Avid Bioservices (NASDAQ: CDMO) reported Q3 EPS of $0.01, $0.02 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $38 million versus the consensus estimate of $36.32 million.

GUIDANCE:

Avid Bioservices sees FY2023 revenue of $145-150 million, versus the consensus of $146 million.

For earnings history and earnings-related data on Avid Bioservices (CDMO) click here.